Skip to main content
SpringerLink
Log in

The EMA’s Pharmacovigilance Working Party (PhVWP) has recommended updates to the product labelling of atomoxetine,

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMA Pharmacovigilance Working Party (PhVWP).Atomoxetine - Updated information on effects on blood pressure and heart rate. PhVWP Monthly Report: 1, No. 1111, 24 Dec 2011. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The EMA’s Pharmacovigilance Working Party (PhVWP) has recommended updates to the product labelling of atomoxetine,. React. Wkly. 1384, 4 (2012). https://doi.org/10.2165/00128415-201213840-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213840-00014

Keywords

Search

Navigation